undamentalytics Newsletter
Sign in

Tempus AI, Inc. (TEM) stock

Add to watchlist

Add holding +

NASDAQ: TEM Nasdaq Health Care Technology Next results ~January 19, 2027

D Fundamentals grade

Tempus AI is a US healthcare technology company that applies artificial intelligence, including generative AI, to laboratory testing. It describes its offering as Intelligent Diagnostics: tests whose results are linked to a patient's own clinical records to guide therapy and treatment decisions. The business runs on the Tempus Platform, which gathers and structures clinical, molecular and imaging data and makes it available to physicians and researchers.

Its products sit in two lines. Diagnostics provides next-generation sequencing, PCR profiling and other pathology testing to healthcare providers, through applications such as Hub. Data and applications — including Insights, Trials, Next and Algos, accessed via the Lens software — serves pharmaceutical and biotechnology firms. The company earns money from diagnostic testing and by licensing de-identified copies of the data it collects, with some data acquired under paid agreements.

Tempus operates five testing laboratories in the United States and says it is connected to more than 55% of the country's oncologists. It launched its platform in 2016 and acquired Ambry Genetics, a hereditary cancer screening firm, in February 2025.

Based on Tempus AI, Inc.'s 10-K filed February 24, 2026.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$25

Revenue-to-maturity model

Base case. Range ~$20–$31. Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Tempus AI, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Tempus AI files

10-Q filed November 2: Tempus AI

Tempus AI generated $1.51bn in revenue over the twelve months to September 2026, a 36.6% increase on the prior year. That pace has cooled from the 50.4% growth recorded a quarter earlier, though it still places the company 4th of 23 among the health care technology stocks we cover. Profitability continues to improve: free-cash-flow margin climbed to -9.1% from -22.1%, while operating margin widened to -18.5% from -21.9%. These gains lift the fundamentals grade from E to D. Despite the progress, our revenue-to-maturity model puts fair value at $24.84 a share, well below the current price of $80.16.

Source: 10-Q filed November 2, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Tempus AI stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.43bn, up 50.4% on a year earlier, slower than 69.8% a quarter earlier. That growth ranks 2 of 23 among the internet and data companies we cover. Free-cash-flow margin fell to -18.4% from -7.3% a year earlier. Operating margin widened to -19.8% from -24.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 1 of our 3 financial-health checks. Our revenue-to-maturity cash-flow model value is $21,816 a share, against a share price of $68.74.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 19, 2027 (estimated)

Tempus AI, Inc.'s trailing-twelve-month revenue grew 36.6% year on year, with a free-cash-flow margin of -9.1%. Where it stands out: revenue growth of 36.6% ranks 4 of 23 health care technology companies we cover. Where it lags: change in growth rate of -13.9pp ranks 21 of 23 health care technology companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 192% in the quarter to 2026-09-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 36.6% over the last 12 months, against a median of 8.8% for health care technology companies we cover.
  • Margins widening. Operating margin is up 3.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.6bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Growth slowing. The growth rate is 13.9 points lower than a quarter earlier.
  • Loss-making. Operating margin is -18.5%: costs exceed revenue.
  • Burning cash. Free cash flow was -9.1% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 76% and a beta of 2.6 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 92 days ranks 19 of 21 health care technology companies we cover (median 58 days).
  • Heavily shorted. 24.9% of the shares available to trade are sold short (3.3 days of average volume to cover).

Latest results: FY2026 Q3

Filed November 2, 2026
Earnings per share
$0.07 against an average estimate of -$0.08: beat by 191.5%
Revenue
$412m, up 23.1% on a year earlier
Guidance given
full year 2026 revenue guidance $1.6bn to $1.61bn (full year 2026); adjusted EBITDA $65m (2026)
Next report
November 2, 2026; average EPS estimate -$0.02

Tempus AI's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+8.7%
  • 1 week+16.9%
  • 1 month+2.4%
  • This year+32.9%
  • 1 year-12.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.5B
Operating margin
-18.5%
Net margin
-12.5%
EPS (TTM, diluted)
$-1.05

Growth

Revenue growth
+36.6%
Change in growth rate
−13.9 pts

Cash

Free cash flow (TTM)
-$137M
FCF margin
-9.1%
Stock pay % of revenue
13.3%

Earnings

Last results
November 2, 2026
Next results (est.)
January 19, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Our research
  2. Results
  3. Our research
  4. Insider trade
  5. Announcement
  6. Announcement
  7. Product
  8. Announcement
  9. Results
  10. Announcement
  11. Announcement
  12. Regulatory
  13. Announcement
  14. Product
  15. Results
  16. Guidance
  17. Agreement
  18. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Tempus AI, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Tempus AI, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.74 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$3.3 ~$2.0–$4.1 Left out: out of range vs price (0.04x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$14 ~$13–$36 Left out: out of range vs price (0.18x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$25 ~$20–$31 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$25 ~$20–$31 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Tempus AI, Inc. with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025Now
Share price$33.76$59.05$78.48
Market value$4m$10.3bn$14.1bn
+ Net debt (− = net cash)−$173m−$396m−$415m
Enterprise value−$169m$9.9bn$13.7bn
Multiples
Price / sales 0.0x8.1x9.4x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.27 +56% $1.6bn +26%
Next −$0.06 +78% $2.0bn +23%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.8% on 90 days ago. In the last 30 days, 0 analysts raised Tempus AI, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Tempus AI, Inc., last 90 days
−$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.26 Current fiscal year, 60 days ago: −$0.26 Current fiscal year, 30 days ago: −$0.26 Current fiscal year, 7 days ago: −$0.26 Current fiscal year, Now: −$0.27 −$0.27 Next fiscal year, 90 days ago: −$0.02 Next fiscal year, 60 days ago: −$0.02 Next fiscal year, 30 days ago: −$0.01 Next fiscal year, 7 days ago: −$0.05 Next fiscal year, Now: −$0.06 −$0.06

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.26−$0.02
60 days ago −$0.26−$0.02
30 days ago −$0.26−$0.01
7 days ago −$0.26−$0.05
Now −$0.27−$0.06

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.08 $0.07 +191.5%
Jun 2026 −$0.15 −$0.04 +73.6%
Mar 2026 −$0.20 −$0.13 +35.3%
Dec 2025 −$0.05 −$0.04 +22.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 30, 2026
  • full year 2026 revenue guidance full year 2026 $1.595bn to $1.605bn Raised
    “Tempus is increasing its full year 2026 revenue guidance to $1.595 to $1.605 billion, which represents ~25% annual growth.” source
  • Adjusted EBITDA 2026 about $65m Non-GAAP Maintained
    “We continue to expect 2026 Adjusted EBITDA to be ~$65 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

20 analysts, Nov 2026
Buy1050%
Hold945%
Sell15%

Monthly trend

  1. Nov 202628920
  2. Oct 202628920
  3. Sep 202628920
  4. Aug 20267716

Counts of recommendations published by analysts covering Tempus AI, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
24.9%
of tradable shares
Days to cover
3.32
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
59%
of shares
Held by insiders
36.1%
of shares
Employees
3,800
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 20252026 to date
Return
TEM+75%+33%
Industry peers (median)−28%−27%
S&P 500+18%+11%
Months that ended higher
TEM58%55%
S&P 50075%46%
Largest fall from a high during the year
TEM−58%−41%
S&P 500−19%−9%

Worst fall since June 14, 2024: 60% from October 8, 2025 to July 29, 2026. Getting back needed a 149% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$41.55 – $88.71
From 52-week high
−11.5%
vs 50-day average
+10.8%
vs 200-day average
+37.7%
Volatility (1 year)
76%
Beta vs S&P 500
2.57

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 6 down
typical move ±6.4%
After a week
7 up, 4 down
typical move ±22.1%
After a month
6 up, 5 down
typical move ±31.0%
Results releasedNext dayS&P 500 next day5 days21 days
July 30, 2026 +5.6% +2.4% +11.0% +54.1%
May 5, 2026 −4.1% +2.2% −15.9% −6.4%
February 24, 2026 −6.2% +1.6% −10.3% −18.4%
January 12, 2026 +1.3% 0.0% +0.8% −19.1%
November 4, 2025 −7.3% −0.8% −19.3% −14.0%
August 8, 2025 +3.5% +0.6% +25.6% +37.9%
May 6, 2025 +8.7% −0.4% +27.4% +8.5%
February 24, 2025 −13.2% −1.0% −25.2% −14.0%
January 13, 2025 −15.2% +0.3% +27.0% +96.9%
November 4, 2024 −3.4% +1.0% +68.5% +25.9%
August 6, 2024 +1.6% +0.2% +11.6% +45.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Tempus AI, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Tempus AI, Inc.
$500M $1B $1.5B $2B FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q1 FY26 Q3 Revenue (TTM), FY24 Q1: $562M Revenue (TTM), FY24 Q2: $595.6M Revenue (TTM), FY24 Q3: $640.4M Revenue (TTM), FY24 Q4: $693.4M Revenue (TTM), FY25 Q1: $803.3M Revenue (TTM), FY25 Q2: $952M Revenue (TTM), FY25 Q3: $1.1B Revenue (TTM), FY25 Q4: $1.3B Revenue (TTM), FY26 Q1: $1.4B Revenue (TTM), FY26 Q2: $1.4B Revenue (TTM), FY26 Q3: $1.5B $1.5B

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $562M
FY24 Q2 $595.6M
FY24 Q3 $640.4M
FY24 Q4 $693.4M
FY25 Q1 $803.3M
FY25 Q2 $952M
FY25 Q3 $1.1B
FY25 Q4 $1.3B
FY26 Q1 $1.4B
FY26 Q2 $1.4B
FY26 Q3 $1.5B
Revenue growth, TTM YoY Tempus AI, Inc.
20% 40% 60% 80% 100% FY25 Q1 FY25 Q3 FY26 Q1 FY26 Q3 Revenue growth, TTM YoY, FY25 Q1: 42.9% Revenue growth, TTM YoY, FY25 Q2: 59.8% Revenue growth, TTM YoY, FY25 Q3: 72.6% Revenue growth, TTM YoY, FY25 Q4: 83.4% Revenue growth, TTM YoY, FY26 Q1: 69.8% Revenue growth, TTM YoY, FY26 Q2: 50.4% Revenue growth, TTM YoY, FY26 Q3: 36.6% 36.6%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q1 42.9%
FY25 Q2 59.8%
FY25 Q3 72.6%
FY25 Q4 83.4%
FY26 Q1 69.8%
FY26 Q2 50.4%
FY26 Q3 36.6%
Operating margin (TTM) Tempus AI, Inc.
-150% -100% -50% 0% FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q1 FY26 Q3 Operating margin (TTM), FY24 Q1: -34.8% Operating margin (TTM), FY24 Q2: -114.8% Operating margin (TTM), FY24 Q3: -108.2% Operating margin (TTM), FY24 Q4: -99.7% Operating margin (TTM), FY25 Q1: -87.9% Operating margin (TTM), FY25 Q2: -24.7% Operating margin (TTM), FY25 Q3: -21.9% Operating margin (TTM), FY25 Q4: -19.9% Operating margin (TTM), FY26 Q1: -19.7% Operating margin (TTM), FY26 Q2: -19.8% Operating margin (TTM), FY26 Q3: -18.5% -18.5%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 -34.8%
FY24 Q2 -114.8%
FY24 Q3 -108.2%
FY24 Q4 -99.7%
FY25 Q1 -87.9%
FY25 Q2 -24.7%
FY25 Q3 -21.9%
FY25 Q4 -19.9%
FY26 Q1 -19.7%
FY26 Q2 -19.8%
FY26 Q3 -18.5%
FCF margin (TTM) Tempus AI, Inc.
-60% -40% -20% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q3 FCF margin (TTM), FY24 Q2: -54.5% FCF margin (TTM), FY24 Q3: -32.3% FCF margin (TTM), FY24 Q4: -30.5% FCF margin (TTM), FY25 Q1: -26.3% FCF margin (TTM), FY25 Q2: -7.3% FCF margin (TTM), FY25 Q3: -22.1% FCF margin (TTM), FY25 Q4: -18.8% FCF margin (TTM), FY26 Q1: -15.6% FCF margin (TTM), FY26 Q2: -18.4% FCF margin (TTM), FY26 Q3: -9.1% -9.1%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -54.5%
FY24 Q3 -32.3%
FY24 Q4 -30.5%
FY25 Q1 -26.3%
FY25 Q2 -7.3%
FY25 Q3 -22.1%
FY25 Q4 -18.8%
FY26 Q1 -15.6%
FY26 Q2 -18.4%
FY26 Q3 -9.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 321 532 693 1,272 1,509
EBITDA −249 −175 −665 −221 −249
Operating income −265 −196 −691 −253 −279
Net income −290 −214 −706 −245 −189
Diluted EPS −$2.65 −$2.10 −$6.23 −$1.41 −$1.05
Growth (year on year)
Revenue — +65.8% +30.4% +83.4% +36.6%
Margins
EBITDA margin −77.6% −32.9% −95.9% −17.4% −16.5%
Operating margin −82.8% −36.9% −99.7% −19.9% −18.5%
Net margin −90.4% −40.3% −101.8% −19.3% −12.5%
Free-cash-flow margin −58.2% −46.8% −30.5% −18.8% −9.1%
Cash flow
Cash from operations −168 −214 −189 −218 −108
Capital spending 18 35 22 21 28
Free cash flow −187 −249 −211 −239 −137
Stock-based pay 0 0 534 125 200
Free cash flow after stock pay −187 −249 −745 −364 −337
Balance sheet
Cash 303 166 341 605 590
Total debt 0 193 168 209 176
Net debt (negative = net cash) −303 27 −173 −396 −415
Diluted shares — — — 174m 180m
Returned to shareholders
Dividends 6 6 6 0 —
Buybacks 0 4 0 3 —
Total returned 6 9 6 3 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · September 30, 2026
What it owns · $2.5bn
Short-term assets $1.1bnLonger-term assets $1.3bn
What it owes, and who funded it · $2.5bn
Short-term liabilities $436mLonger-term liabilities $1.5bnShareholders' equity $500m
  • Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $436m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.1bn short-term assets against $1.5bn of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$279m against $47m of interest.

From Tempus AI, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$6.6M
R&D spending
13.1%
of revenue
Sales & admin spending
58.2%
of revenue
Days sales outstanding
92 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care technology
Last 12 months unless stated TEM WAY OMCL TDOC GDRX VEEV Median
Revenue, last 12 months $1.5bn $1.3bn $1.2bn $2.5bn $785m $3.5bn $292m
Revenue growth, last 12 months 36.6% 21.4% 8.5% −2.4% −1.8% 16.5% 8.8%
Revenue growth, 3-year average — — 0.3% −1.5% 1.8% 15.7% 0.8%
Revenue growth, latest quarter 23.1% 21.2% 7.4% −3.4% −1.3% 17.6% 7.4%
Gross margin — — 44.8% 70.2% — 75.0% 58.6%
Operating margin −18.5% 21.9% 4.6% −6.6% 9.5% 29.9% −12.5%
Operating margin, 3-year average −49.5% 19.1% 0.8% −18.8% 5.6% 26.5% −18.8%
Net margin −12.5% 10.7% 3.1% −6.3% 2.1% 29.3% −12.5%
Cash from operations / revenue −7.2% 24.9% 14.6% 10.9% 25.7% 48.2% 9.7%
Free-cash-flow margin −9.1% 20.9% 11.4% 10.6% 25.1% 47.4% 9.2%
Free-cash-flow margin, 3-year average −21.2% 19.4% 12.0% 11.5% 21.7% 43.3% 8.2%
Stock pay / revenue 13.3% 4.9% 3.6% 2.1% 9.7% 14.3% 9.5%
Change in share count — 9.7% −1.5% 2.9% −9.8% −0.1% 2.9%

Median of all 23 companies we cover in health care technology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

23 health care technology companies
Measure Company Peer median Rank
Revenue growth Growth 36.6% 8.8% 4 of 23
Change in growth rate Growth -13.9pp -0.3pp 21 of 23
Operating margin Profitability -18.5% -6.6% 12 of 22
Net margin Profitability -12.5% -12.5% 12 of 23
Free-cash-flow margin Cash generation -9.1% 10.6% 14 of 22
Stock pay as % of revenue Cash generation 13.3% 9.7% 15 of 22
Days sales outstanding Balance sheet 92 days 58 days 19 of 21

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Diagnostics $955M 75.1% ▲ 111.5%
Data and Applications $316M 24.9% ▲ 30.9%
Insights Product $258M 81.4% ▲ 38.0%
Trials Product $38.5M 12.2% ▼ 9.2%
AI Applications $20.1M 6.4% ▲ 63.4%

From Tempus AI, Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$6.4B
Institutions reporting
483
Shares held vs prior quarter
▲ 5.1%
Positions opened / closed
115 / 58

Top buyers and sellers, Q2 2026: 277 institutions bought and 175 sold ; the biggest buyer was Goldman Sachs Group Inc (+2.5M shares) and the biggest seller Gc Wealth Management Ria, LLC (−4.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
ARK Investment Management LLC $581M 10.0M 9.1% ▲ 4.3%
Blackrock, Inc. $480M 8.3M 7.5% ▼ 7.6%
Baillie Gifford & Co $474M 8.2M 7.4% ▼ 5.3%
Softbank Group Corp. $313M 5.4M 4.9% 0.0%
Jpmorgan Chase & Co $291M 5.0M 4.5% ▲ 1.1%
Vanguard Capital Management LLC $289M 5.0M 4.5% ▲ 1.4%
Vanguard Portfolio Management LLC $285M 4.9M 4.4% ▲ 5.0%
Sumitomo Mitsui Trust Group, Inc. $237M 4.1M 3.7% ▼ 5.5%
Amova Asset Management Americas, Inc. $237M 4.1M 3.7% ▼ 5.5%
Goldman Sachs Group Inc $218M 3.8M 3.4% ▲ 194.4%
Morgan Stanley $212M 3.7M 3.3% ▲ 75.3%
Franklin Resources Inc $194M 3.4M 3.0% ▲ 29.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Tempus AI, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $2.7M 12 trades by 1 insider, last 12 months Insider sales History → $209M 247 trades by 11 insiders · 93% under pre-set plans
Net ▼ $206M net selling
Insider Date Trade Shares Price Value
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 13,209 $72.31 $955,143
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 14,237 $71.56 $1M
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 5,486 $70.58 $387,202
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 1,300 $69.28 $90,064
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 6,636 $68.00 $451,248
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 9,132 $67.36 $615,132
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 2,071 $72.31 $149,754
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 2,167 $71.56 $155,071
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 824 $70.58 $58,158
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 195 $69.28 $13,510
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 961 $68.00 $65,348
Lefkofsky Eric P CEO and Chairman October 27, 2026 Sell pre-set plan 1,282 $67.36 $86,356

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 3 trades and filings

In the last 12 months, 1 member of Congress disclosed 1 purchase and 0 sales of Tempus AI, Inc. shares.

  • Nancy Pelosi(D-CA 11):Purchase (option), $50,001 - $100,000, traded January 16, 2026, filed January 23, 2026
  • Robert P. Bresnahan, Jr.(R-PA 8):Purchase, $1,001 - $15,000, traded May 9, 2025, filed June 9, 2025
  • Nancy Pelosi(D-CA 11):Purchase (option), $50,001 - $100,000, traded January 14, 2025, filed January 17, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 19, 2027 estimated from the company's past filing pattern, not announced

  • November 2, 2026
  • July 30, 2026
  • May 5, 2026
  • February 24, 2026
  • January 12, 2026
  • November 4, 2025

Recent SEC filings

Data status

When each part of this page on Tempus AI, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Tempus AI, Inc. in brief

What does Tempus AI, Inc. do?
Tempus AI, Inc. is a US-listed company in the health care technology industry. Its financial year ends in December.
What is Tempus AI, Inc.'s stock ticker?
Tempus AI, Inc. trades under the ticker TEM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Tempus AI, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Tempus AI, Inc. reported revenue of $1.5B, 36.6% higher than a year earlier, according to its SEC filings.
What is Tempus AI, Inc.'s free cash flow?
Tempus AI, Inc.'s free-cash-flow margin is -9.1% of revenue over the trailing twelve months, ranking 14 of the 22 health care technology companies we cover.
Who are Tempus AI, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are ARK Investment Management LLC, Blackrock, Inc. and Baillie Gifford & Co. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Tempus AI, Inc.'s market cap?
On November 2, 2026, Tempus AI, Inc.'s market capitalisation was about $14.1B and net debt of -$415M. Market figures come from third-party market data and may be delayed.
Who are Tempus AI, Inc.'s competitors?
In our Health Care Technology peer group, the companies closest to Tempus AI, Inc. are Waystar Holding Corp., Omnicell, Inc., Teladoc Health, Inc., Goodrx Holdings, Inc. and Veeva Systems Inc. The side-by-side comparison below sets their revenue, margins and growth against Tempus AI, Inc.'s.
Are insiders buying or selling Tempus AI, Inc. stock?
Over the last 12 months, Tempus AI, Inc.'s directors and officers reported 12 open-market purchases and 247 sales on Form 4. The insider trading page charts every trade.
When is Tempus AI, Inc.'s next earnings date?
Around January 19, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Tempus AI, Inc. announces its own schedule.